

# Quantitative 7T Relaxographic, Volumetric and DCE Assessment of Thalamic Changes in Early Alzheimer's Disease

V. C. Anderson<sup>1</sup>, D. P. Lenar<sup>1</sup>, J. F. Quinn<sup>2</sup>, W. J. Woodward<sup>3</sup>, J. A. Kaye<sup>2</sup>, and W. D. Rooney<sup>3</sup>

<sup>1</sup>Neurological Surgery, Oregon Health & Science University, Portland, OR, United States, <sup>2</sup>Neurology, Oregon Health & Science University, Portland, OR, United States, <sup>3</sup>Advanced Imaging Research Center, Oregon Health & Science University, Portland, OR, United States

**Introduction:** Longitudinal water proton (<sup>1</sup>H<sub>2</sub>O) relaxation time constants (T<sub>1</sub>) have been used extensively to probe the interactions of water and macromolecules in the human brain.<sup>1</sup> While an increase in gray matter <sup>1</sup>H<sub>2</sub>O T<sub>1</sub> values with age has been observed by many groups,<sup>2</sup> the physiological basis of this finding remains unclear. Brain tissue <sup>1</sup>H<sub>2</sub>O R<sub>1</sub> (≡ 1/T<sub>1</sub>) values are strongly associated with macromolecular volume fraction (f<sub>M</sub>; an intensive property)<sup>3</sup> which may decrease with age and precede net tissue volume loss (atrophy; an extensive property). Volume loss in the subcortical gray is a common feature of the aging brain and has recently been identified in the thalamus of subjects with Alzheimer's disease (AD).<sup>4</sup> Atrophic changes are associated with expansion of CSF spaces and could, through partial volume effects, lead to increased T<sub>1</sub> values. Vascular ultrastructure is also known to be abnormal in early AD<sup>5</sup> and could, through increased blood water content, contribute to altered <sup>1</sup>H<sub>2</sub>O T<sub>1</sub> values. The aim of this study was to examine the extent to which <sup>1</sup>H<sub>2</sub>O T<sub>1</sub> values reflect changes in tissue and/or vascular water content in the thalamus in early AD.

**Methods:** 3 subjects with mild AD (71 ± 5 yrs; 3 males) and 8 cognitively normal (CN) age-matched controls (64 ± 6 yrs; 4 male/4 female) provided informed consent and were enrolled. All AD subjects had onset of symptoms after age 40, Clinical Dementia Rating<sup>6</sup> of 0.5, MMSE 20-27, deficit in another non-cognitive domain, and progressive worsening of memory. CN subjects had no memory complaints, MMSE 28-30, and no history of neurologic disease. MR data were acquired on a 7T whole-body instrument (Siemens MAGNETOM) with 8-channel phased array RF transmit/receive head coil (Rapid Biomedical). Full volume (96 slices) IR-MPRAGE acquisitions (TR/TE= 3500/2.3 ms; FA= 6°; 114x192 matrix; slice thickness 2 mm) centered on the lateral ventricles were sampled at different inversion times (TI= 300, 1800, 3200 ms; and no inversion pulse). FOV was adjusted to provide 1.3 mm<sup>2</sup> in plane resolution. IR datasets were collected prior to and 10, 24, 35, and 57 min post (CR; gadoteridol; Bracco Diagnostics) injection (0.11 mmol/kg; 2 mL/s; Spectris MR Injection System, Medrad). Parametric maps were prepared after co-registration of IR image sets and voxelwise fitting of signal intensity to a two parameter single exponential IR equation using a gradient expansion algorithm. IR-MPRAGE structural images were also acquired (TR/TE/TI 2800/2.8/1100 ms; FA 6°; 256x256 matrix and FOV; 1 mm slice). Volumes of interest (VOI) were segmented automatically by application of a sub-cortical mask prepared using FIRST, part of FMRIB's software library (FSL, Oxford), after transformation and affine registration of the parametric map and structural image to MNI 152 standard space.<sup>7</sup> Sub-cortical volumes were normalized to total intracranial volume (estimated with SIENAX,<sup>8</sup> another part of FSL). <sup>1</sup>H<sub>2</sub>O T<sub>1</sub> values were determined after fitting VOI histograms to a Gaussian function. Intravascular water fraction (p<sub>b</sub>) was determined from an equation for two-site (blood plasma, extravascular extracellular space) exchange that assumes equilibrium transendothelial water exchange, fixed intravascular <sup>1</sup>H<sub>2</sub>O lifetime (τ<sub>b</sub>= 280 ms)<sup>9</sup>, and negligible CR extravasation (K<sup>trans</sup> ≈ 0).<sup>10</sup>

**Results and Discussion:** Figure 1 shows a T<sub>1</sub> map from a 66 year old AD male with VOIs indicated. Mean <sup>1</sup>H<sub>2</sub>O T<sub>1</sub> values for AD and CN groups are presented in Table 1. The values we report are in reasonable agreement with those obtained previously at 7T.<sup>3</sup> Compared to CN subjects, <sup>1</sup>H<sub>2</sub>O T<sub>1</sub> values in the thalamus are increased by about 4% (P= 0.05) in AD subjects, with smaller (non-significant) increases in other structures. No effect of gender or laterality on T<sub>1</sub> values was found. Figure 2 (top) shows the mean volume of subcortical structures. Compared to CN subjects, thalamic volume is reduced by 9.6% (P= 0.04) in AD subjects. No significant differences in volume were observed between groups in other structures. The lower panel in Figure 2 shows the R<sub>1</sub> response of tissue in the thalamus (R<sub>t</sub>) compared to blood (R<sub>b</sub>) after CR injection and the best fit of averaged group data to the two-site transendothelial exchange model. The analysis reveals no difference in p<sub>b</sub> between AD and CN groups. Taken together, our findings are consistent with the idea that increased <sup>1</sup>H<sub>2</sub>O T<sub>1</sub> values in the thalamus in early AD reflect, at least in part, neurodegenerative (macro-molecular loss) processes and that changes in the vasculature which increase blood water content (e.g., vasodilation or angiogenesis) if present, are small. However, our conclusions are based on only a few subjects and a model that neglects CR extravasation. A more thorough analysis is necessary to substantiate these results.




Table 1. <sup>1</sup>H<sub>2</sub>O T<sub>1</sub> values of subcortical VOIs

VOI	AD (N= 3)	CN (N= 8)	Difference (%)
Thalamus	1449 ± 32	1385 ± 58	4.4
Caudate	1594 ± 52	1565 ± 32	1.8
Putamen	1513 ± 26	1480 ± 30	2.2
Pallidum	1267 ± 66	1227 ± 43	3.2

<sup>a</sup>Mean (ms) ± sd averaged over right and left hemispheres




Figure 2 (top) shows the mean volume of subcortical structures. Compared to CN subjects, thalamic volume is reduced by 9.6% (P= 0.04) in AD subjects. No significant differences in volume were observed between groups in other structures. The lower panel in Figure 2 shows the R<sub>1</sub> response of tissue in the thalamus (R<sub>t</sub>) compared to blood (R<sub>b</sub>) after CR injection and the best fit of averaged group data to the two-site transendothelial exchange model. The analysis reveals no difference in p<sub>b</sub> between AD and CN groups. Taken together, our findings are consistent with the idea that increased <sup>1</sup>H<sub>2</sub>O T<sub>1</sub> values in the thalamus in early AD reflect, at least in part, neurodegenerative (macro-molecular loss) processes and that changes in the vasculature which increase blood water content (e.g., vasodilation or angiogenesis) if present, are small. However, our conclusions are based on only a few subjects and a model that neglects CR extravasation. A more thorough analysis is necessary to substantiate these results.

**References:** 1. Cho, et al., *Magn Reson Imaging* 15, 1133-1143 (1997); Suzuki, et al., *Magn Reson Imaging* 24, 877-887 (2006); Oros-Peusquens, et al., *PISMRM* 16, 1417 (2008) 2. Sullivan, et al., *Neurobiol Aging* 25, 185-192 (2004) 3. Rooney, et al., *Magn Reson Med* 57, 308-318 (2007) 4. de Jong, et al., *Brain* 131, 3277-3285 (2008) 5. Farkas, Luiten, *Prog Neurobiol* 64, 575-611 (2001); Zlokovic, *Trends Neurosci* 28, 202-208 (2005); Modrego, et al., *Am J Alzheimers Dis Other Dement* 23, 91-96 (2008). 6. Berg, *Psychopharmacol Bull* 24, 637-639 (1988) 7. Smith, et al., *Neuroimage* 23, 208-219 (2004); Patenaude, et al., *Hum Brain Map Conf* (2007) 8. Smith, et al., *Neuroimage* 17, 479-489 (2002) 9. Rooney, et al., *PISMRM* 11, 2188 (2003) 10. Njus, et al. *PISMRM* 15, 2193 (2007); Li, et al., *Magn Reson Med* 54, 1351-1359 (2005).

**Grant Support:** NIH AG 033638, NIH EB 007258, Oregon Partnership for Alzheimer's Research, and Oregon Opportunity